Why keeping only popular parts of ACA won’t work

While President-elect Donald Trump may be offering a compromise on the Affordable Care Act (ACA) by keeping its ban on insurers denying coverage based on preexisting conditions, it’s doomed to fail if insurers can charge sick people more.

That’s according to Jonathan Gruber, PhD, a health economist at the Massachusetts Institute of Technology who helped the craft the ACA. Writing in the New York Times, Gruber said the pre-ACA insurance market, the primary source of profit was denying coverage to sick individuals. If insurers are allowed to charge much higher prices to people with pre-existing conditions, the coverage requirement won’t help.

“The insurer could offer coverage, but say that any breast-cancer survivor had to pay, say, five times more than everyone else. Both would be perfectly legal if the Affordable Care Act was repealed and replaced under Mr. Trump’s principles,” Gruber wrote. “If we say that insurers have to pay for breast-cancer treatment for their insured but allow them to set unaffordable prices or deny insurance altogether, how does that solve the problem?”

For more on why Gruber thinks any ACA replacement plan will come with serious financial risk, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup